Observational Study in Type 2 Diabetics Failing on Oral Antidiabetic Therapy and Starting on Insulin Treatment (HA-BOT)

Novo Nordisk

Status: Completed

Conditions: Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: insulin detemir

Study type: Observational

Funder types: Industry

Identifiers

NCT00865397

NN304-3699

Details and patient eligibility

About

This study is conducted in Europe. The aim of this observational study is to evaluate glycaemic control in subjects with type 2 diabetes using once daily Levemir® as initiation of insulin therapy in Hungary.

Enrollment: 1,032 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient with type 2 diabetes inadequately controlled by OAD therapy based on the discretion of individual physician
• Patient willing to sign informed consent
• Particular attention should be paid to age limits, indications and contraindications and the drug interactions that are listed within the product labels

Exclusion criteria

• Subjects with diagnosed type 1 diabetes mellitus
• Subjects who are unlikely to comply with observational plan, (e.g., uncooperative attitude, inability to return for further visits)
• Subjects with hypersensitivity to Levemir® or to any of the ingredients
• Women of childbearing potential, who are pregnant, breast-feeding or intend to become pregnant within next 12 months.

Trial design

1,032 participants in 1 patient group

A

Treatment:

Drug: insulin detemir